Amendments to the ~~Claims~~:

1. (Currently Amended) A method of detecting the presence of a polypeptide in a sample comprising contacting the sample with a homogeneous population of a detectable virus expressing on its surface a ligand for the polypeptide and detecting binding of the virus to the sample, thus detecting the presence of the polypeptide in the sample.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) A method of detecting the presence of a selected polypeptide in a sample comprising contacting the sample with a homogeneous population of a detectable virus expressing on its surface a ligand previously demonstrated to specifically bind the selected polypeptide and detecting binding of the virus to the sample, thus detecting the presence of the selected polypeptide in the sample.

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) A method of detecting the presence of a selected cellular protein on the surface of a cell comprising contacting the cell with a homogeneous population of a detectable virus expressing on its surface a ligand previously demonstrated to specifically bind the selected cellular protein and detecting binding of the virus to the cell, thus detecting the presence of the selected cellular protein on the surface of the cell.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Currently Amended) A method of detecting the presence of a selected polypeptide in a sample comprising contacting the sample with a homogeneous population of a detectable bacteriophage expressing on its surface at least 10 copies of a ligand for the selected polypeptide and detecting binding of the bacteriophage to the sample, thus detecting the presence of the selected polypeptide in the sample.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Currently Amended) A method of detecting the presence of a selected cellular protein on the surface of a cell comprising contacting the cell with a homogeneous population of a detectable bacteriophage expressing on its surface a at least 10 copies of a ligand for the selected cellular protein and detecting binding of the bacteriophage to the cell, thus detecting the presence of the selected cellular protein on the surface of the cell.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Previously Added) The method of claim 1, wherein the virus is a bacteriophage.

46. (Previously Amended) The method of claim 1, wherein the polypeptide is a cellular protein.

47. (Previously Added) The method of claim 1, wherein the sample is a clinical sample.

48. (Previously Added) The method of claim 5, wherein the virus is a bacteriophage.

49. (Previously Amended) The method of claim 5, wherein the polypeptide is a cellular protein

50. (Previously Added) The method of claim 5, wherein the sample is a clinical sample.

51. (Previously Added) The method of claim 9, wherein the virus is a bacteriophage.

52. (Cancelled)

53. (Previously Added) The method of claim 9, wherein the cellular protein is a receptor or channel protein.

54. (Previously Added) The method of claim 9, wherein the cellular protein is N-methyl D-aspartate receptor.

55. (Previously Added) The method of claim 9, wherein the cells are in culture.

56. (Previously Added) The method of claim 9, wherein the cells are in vivo.

57. (Previously Added) The method of claim 9, wherein the ligand expressed on the surface of the virus is selected from the group consisting of the peptide whose amino acid sequence is set forth as SEQ ID NO:2 and the peptide whose amino acid sequence is set forth as SEQ ID NO:3.

58. (Previously Added) The method of claim 17, wherein the bacteriophage expresses on its surface at least 100 copies of the ligand.

59. (Previously Added) The method of claim 17, wherein the bacteriophage expresses on its surface at least 400 copies of the ligand.

60. (Previously Amended) The method of claim 17, wherein the polypeptide is a cellular protein.

61. (Previously Added) The method of claim 17, wherein the sample is a clinical sample.

62. (Previously Added) The method of claim 22, wherein the bacteriophage expresses on its surface at least 100 copies of the ligand.

63. (Previously Added) The method of claim 22, wherein the bacteriophage expresses on its surface at least 400 copies of the ligand.

64. (Cancelled)

65. (Previously Added) The method of claim 22, wherein the cellular protein is a receptor or channel protein.

66. (Previously Added) The method of claim 22, wherein the cellular protein is N-methyl D-aspartate receptor.

67. (Previously Added) The method of claim 22, wherein the cells are in culture

68. (Previously Added) The method of claim 22, wherein the cells are in vivo.

69. (Previously Added) The method of claim 22, wherein the ligand expressed on the surface of the virus is selected from the group consisting of the peptide whose amino acid sequence is set forth as SEQ ID NO:2 and the peptide whose amino acid sequence is set forth as SEQ ID NO:3.

70. (Currently Added) The method of claim 1 wherein the virus expresses on its surface at least 10 copies of the ligand.

71. (Currently Added) The method of claim 5 wherein the virus expresses on its surface at least 10 copies of the ligand.

72. (Currently Added) The method of claim 9 wherein the virus expresses on its surface at least 10 copies of the ligand.

73. (Currently Added) The method of claim 1 wherein the virus is a filamentous bacteriophage and the ligand is fused to phage coat protein pVIII.

74. (Currently Added) The method of claim 5 wherein the virus is a filamentous bacteriophage and the ligand is fused to phage coat protein pVIII.

75. (Currently Added) The method of claim 9 wherein the virus is a filamentous bacteriophage and the ligand is fused to phage coat protein pVIII.